

# Pyogenic Granuloma – A Common Benign Vascular Tumor with Variable Clinical Presentation: New Findings and Treatment Options

Uwe Wollina<sup>1\*</sup>, Dana Langner<sup>1</sup>, Katlein França<sup>2</sup>, Serena Gianfaldoni<sup>3</sup>, Torello Lotti<sup>4</sup>, Georgi Tchernev<sup>5</sup>

<sup>1</sup>Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; <sup>2</sup>Department of Dermatology & Cutaneous Surgery, and Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami Miller School of Medicine, Miami, FL, USA; <sup>3</sup>Dermatological Department University of Pisa, Pisa, Italy; <sup>4</sup>Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy; <sup>5</sup>Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, and Onkoderma-Policlinic for Dermatology and Dermatologic Surgery, Sofia, Bulgaria

## Abstract

Pyogenic granuloma is a common benign vascular tumour occurring in all ages. Both skin and mucous membranes can be affected. Of pathogenetic importance are trauma, BRAF mutations and probably herpes virus type 1, Orf virus and/or human papilloma virus type 2. The tumour consists of capillary proliferations, venules and fibromyxoid stroma. The development of a lesion occurs in three stages and bleeding is a common symptom. The tumour can mimic various other vascular lesions, solid tumours, and soft tissue infections. In recent years, targeted tumour therapies have become the most common cause of drug-induced pyogenic granulomas. The backbone of treatment is surgical procedures including laser therapy. New developments in medical drug therapy include topical and systemic beta-adrenergic receptor antagonists timolol and propranolol. Drug therapy is an alternative for young children, ocular and periungual pyogenic granuloma.

**Citation:** Wollina U, Langner D, França K, Gianfaldoni S, Lotti T, Tchernev G. Pyogenic Granuloma – A Common Benign Vascular Tumor with Variable. Open Access Maced J Med Sci. 2017 Jul 25; 5(4):423-426. <https://doi.org/10.3889/oamjms.2017.111>

**Keywords:** Pyogenic granuloma; benign vascular tumours; BRAF mutations; virus; surgery; beta-adrenergic receptor antagonists.

**\*Correspondence:** Uwe Wollina, Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Friedrichstr. 41, 01067 Dresden, Germany. E-mail: wollina-uw@khd.de

Received: 23-Apr-2017; Revised: 02-May-2017; Accepted: 07-May-2017; Online first: 13-Jul-2017

**Copyright:** © 2017 Uwe Wollina, Dana Langner, Katlein França, Serena Gianfaldoni, Torello Lotti, Georgi Tchernev. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

**Funding:** This research did not receive any financial support.

**Competing Interests:** The authors have declared that no competing interests exist.

## Introduction

Pyogenic granuloma (PG) – also known as lobular capillary hemangioma - is a benign vascular tumour that occurs on the skin and mucous membranes, occasional it can be found subcutaneously or intravascularly. PG can arise spontaneously, in sites of injury, or within capillary malformations [1].

PG has been associated with certain medications such as oral contraceptives, retinoids, gefitinib, cabecitabine, and afatinib [2-5]. Most tumours occur as solitary lesions, but multiple grouped or disseminated tumours have been described. Multiple disseminated tumours are an adverse cutaneous effect of melanoma treatment with

selective BRAF inhibitors like vemurafenib or encorafenib [6]. Multiple periungual PGs occur with targeted oncological therapies using epidermal growth-factor receptor inhibitors or mitogen-activated protein kinase (MEK) inhibitors [7], and rituximab [8].

## Histology and Pathogenesis

Histologically, PG is composed of capillaries and venules with plump endothelial cells separated into lobules by fibromyxoid stroma. The development can be classified into (i) cellular phase, (ii) capillary phase or vascular phase, and (iii) involutionary phase. Slow fibromatous regression is seen in untreated

lesions after longer time [9]. The endothelial cells in PG express CD34, ICAM-1, VCAM-1 associated with an increased microvascular density [10].

Recently, BRAF c.1799T>A mutation had been identified in endothelial cells as a major driver mutation in the pathogenesis of PG [11]. This explains the occurrence of multiple PGs in patients treated with BRAF inhibitors.

The participation of viral particles in PG pathogenesis has been discussed. Alpha-herpes viridae type 1 is considered as a possible indirect factor stimulating angiogenesis in PG. In some patients, dermatotropic parapoxvirus (Orf) could be identified by polymerase-chain reaction (PCR). Human papilloma virus DNA could be identified in 44% of these lesions with HPV type 2 as the most common [12-15].

## Clinical Presentation

PG occurs in all age groups. There is no clear predominance of a gender. PG appear as small or large, smooth or lobulated, reddish exophytic vascular nodules that can grow rapidly (Fig. 1). Larger lesions become lobulated and sometimes develop into mushroom-like, pedunculated tumours (Fig. 2). PGs have a tendency to bleed profusely. Bleeding is the leading symptom for a visit to the doctor's office.



Figure 1: Pyogenic granuloma (PG) – common clinical presentations. (a) Nodular PG of the lower lip; (b) Collerette-like demarcation of a PG on the knee; (c) Flat, keratotic PG on the lower leg. (d) Marked collerette with a flat nodule on the lower arm

Hands, lower lips and gingiva are most frequently affected [1]. In one study, PG was the most common benign lesion of the lips responsible for 48% of all cases [16]. Another study from Brazil investigated gingival lesions in children and adolescents. PGs accounted for 42% of all gingival

lesions [17]. Considering the nail organ, most lesions occur on the nail folds, but subungual tumours have also been observed [18].

During pregnancy, large intraoral PGs may develop [19]. Uncommon sites are vulva and penis, oesophagus, gut, and tracheobronchial tree [20-24]. Gastrointestinal PG can cause severe anaemia [25]. Extremely rare are intravascular tumours which bear the risk of thrombosis [26].




Figure 2: Pyogenic granuloma (PG) – less common clinical findings. (a) Larger mushroom-like, thrombosed PG – melanoma-like; (b) Mushroom-like PG on the finger bow with a wet surface and maceration of the surrounding skin – pyoderma-like; (c) Large pedunculated PG of the upper lip – hemangioma like; (d) Large, firm nodular PG of the palm – non-melanoma skin cancer-like

Portwine stains are at risk for secondary PG [27]. Their treatment with vascular lasers may induce PG as well [28].

Satellitosis is a very uncommon phenomenon in benign tumours. Nevertheless, satellitosis has been observed in paediatric PG [29, 30]. Deep-seated PG is a rare entity with 3.8% of all PGs diagnosed in childhood [31].

## Differential diagnoses

PG can mimic other vascular tumours, including Kaposi form hemangioendothelioma,

infantile hemangiomas, vascular malformations, and Kaposi sarcoma. In so-called “Kaposi-like PG” human herpes virus type 8 could be identified. These lesions are true Kaposi sarcomas, not PG [32]. Other malignancies that can mimic PC are malignant lymphomas, basal cell carcinoma, or malignant melanoma [33-35]. In immunocompromised patients, deep soft tissue infections like phaeohyphomycosis or bartonellosis should be considered [36, 37].

## Treatment

The usual treatment for PG consists of excision, the treatment with the lowest rate of recurrence [1]. Depending on the area, size and patient wishes, curettage, electrocautery, radiosurgery, cryosurgery, sclerotherapy, or laser treatment are alternative options. Among lasers, diode lasers of wave-length between 808 to 980 nm [38-40] or solid-state neodymium - yttrium aluminium garnet (Nd:YAG) lasers [41, 42], erbium-YAG and CO<sub>2</sub> lasers [43, 44] have all been used successfully. Erbium-YAG laser lacks coagulation, what may become a disadvantage in larger lesions. Successful photodynamic therapy (PDT) with 5-aminolevulinic acid has been reported for a single PG on a finger [45]. A possible advantage of PDT compared to laser removal has yet not proved.

In small children, topical or oral medical therapy with beta-adrenergic receptor antagonists timolol or propranolol seems to be effective [46]. Periungual PGs have been treated off-label with topical 1% propranolol cream [47]. For PG on ocular surfaces medical treatment with topical 0.5 % timolol eye drops twice daily for a minimum of 21 days, is an option [48]. The treatment, either oral or topical, warrants monitoring. Since systemic absorption can occur even after timolol eye drops, patients should be monitored for bradycardia, hypotension, hypoglycemia, and bronchoconstriction. In elderly patients, syncope and falls have been observed [49, 50].

## References

- Giblin AV, Clover AJ, Athanassopoulos A, Budny PG. Pyogenic granuloma - the quest for optimum treatment: an audit of treatment of 408 cases. *J Plast Reconstr Aesthet Surg.* 2007;60(9):1030-5. <https://doi.org/10.1016/j.bjps.2006.10.018> PMID:17478135
- Simmons BJ, Chen L, Hu S. Pyogenic granuloma association with isotretinoin treatment for acne. *Australas J Dermatol.* 2016;57(4):e144-5. <https://doi.org/10.1111/ajid.12418> PMID:27885661
- Massa A, Antunes A, Varela P. Pyogenic granuloma in a patient on gefitinib. *Acta Med Port.* 2016;29(6):416. <https://doi.org/10.20344/amp.6343> PMID:27865223
- Fujiwara C, Motegi SI, Sekiguchi A, Amano H, Ishikawa O. Pyogenic granuloma possibly associated with capecitabine therapy. *J Dermatol.* 2016. <https://doi.org/10.1111/1346-8138.13691>
- Inoue A, Sawada Y, Nishio D, Nakamura M. Pyogenic granuloma caused by afatinib: Case report and review of the literature. *Australas J Dermatol.* 2017;58(1):61-2. <https://doi.org/10.1111/ajid.12423> PMID:26603180
- Henning B, Stieger P, Kamarachev J, Dummer R, Goldinger SM. Pyogenic granuloma in patients treated with selective BRAF inhibitors: another manifestation of paradoxical pathway activation. *Melanoma Res.* 2016;26(3):304-7. <https://doi.org/10.1097/CMR.0000000000000248> PMID:27116335
- Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, Baran R. Nail toxicities induced by systemic anticancer treatments. *Lancet Oncol.* 2015;16(4):e181-9. [https://doi.org/10.1016/S1470-2045\(14\)71133-7](https://doi.org/10.1016/S1470-2045(14)71133-7)
- Wollina U. Multiple eruptive periungual pyogenic granulomas during anti-CD20 monoclonal antibody therapy for rheumatoid arthritis. *J Dermatol Case Rep.* 2010;4(3):44-6. <https://doi.org/10.3315/jdcr.2010.1050> PMID:21886749 PMCID:PMC3157817
- Marla V, Shrestha A, Goel K, Shrestha S. The histopathological spectrum of pyogenic granuloma: A case series. *Case Rep Dent.* 2016;2016:1323798. <https://doi.org/10.1155/2016/1323798>
- Syedmajidi M, Shafae S, Hashemipour G, Bijani A, Ehsani H. Immunohistochemical evaluation of angiogenesis related markers in pyogenic granuloma of gingiva. *Asian Pac J Cancer Prev.* 2015;16(17):7513-6. <https://doi.org/10.7314/APJCP.2015.16.17.7513> PMID:26625754
- Groesser L, Peterhof E, Evert M, Landthaler M, Berneburg M, Hafner C. BRAF and RAS mutations in sporadic and secondary pyogenic granuloma. *J Invest Dermatol.* 2016;136(2):481-6. <https://doi.org/10.1038/JID.2015.376>
- El Hayderi L, Rübber A, Nikkels AF. [The alpha-herpesviridae in dermatology: Herpes simplex virus types I and II. German version]. *Hautarzt.* 2017;68(3):181-6. <https://doi.org/10.1007/s00105-016-3929-5> PMID:28197699
- Biyik Ozkaya D, Taskın B, Tas B, Asıran Serdar Z, Demirkesen C, Su O, Onsun N. Poxvirus-induced angiogenesis after a thermal burn. *J Dermatol.* 2014;41(9):830-3. <https://doi.org/10.1111/1346-8138.12589> PMID:25110123
- Ran M, Lee M, Gong J, Lin Z, Li R. Oral acyclovir and intralesional interferon injections for treatment of giant pyogenic granuloma-like lesions in an immunocompromised patient with human Orf. *JAMA Dermatol.* 2015;151(9):1032-4. <https://doi.org/10.1001/jamadermatol.2015.0760> PMID:25946461
- Vázquez-Martínez OT, González-Betancourt A, Barboza-Cerda MC, González-González SE, Lugo-Trampe Á, Welsh O, Rojas-Martínez A, Martínez-Rodríguez HG, Ocampo-Candiani J, Ortiz-López R. Human papillomavirus type 2 associated with pyogenic granuloma in patients without clinical evidence of warts. *Int J Dermatol.* 2015;55(7):745-50. <https://doi.org/10.1111/ijd.12982> PMID:26492599
- Tobouti PL, Olegário I, de Sousa SC. Benign vascular lesions of the lips: Diagnostic approach. *J Cutan Pathol.* 2017;44(5):451-5. <https://doi.org/10.1111/cup.12911> PMID:28111788
- daSilva FC, Piazzetta CM, Torres-Pereira CC, Schussel JL, Amenábar JM. Gingival proliferative lesions in children and adolescents in Brazil: A 15-year-period cross-sectional study. *J Indian Soc Periodontol.* 2016;20(1):63-6. <https://doi.org/10.4103/0972-124X.168493> PMID:27041840 PMCID:PMC4795138
- Wollina U. Subungual telangiectatic granuloma. *Dtsch Arztebl Int.* 2017;114(8):136. PMID:28302264 PMCID:PMC5374259
- Silva de Araujo Figueiredo C, Gonçalves Carvalho Rosalem C, Costa Cantanhede AL, Abreu Fonseca Thomaz ÉB, Fontoura Nogueira da Cruz MC. Systemic alterations and their oral manifestations in pregnant women. *J Obstet Gynaecol Res.* 2017;43(1):16-22. <https://doi.org/10.1111/jog.13150> PMID:28074549



20. Abreu-Dos-Santos F, Câmara S, Reis F, Freitas T, Gaspar H, Cordeiro M. Vulvar lobular capillary hemangioma: A rare location for a frequent entity. *Case Rep Obstet Gynecol*. 2016;2016:3435270. <https://doi.org/10.1155/2016/3435270> PMID:16243130
21. Katmeh RF, Johnson L, Kempley E, Kotecha S, Hamarneh W, Chitale S. Pyogenic granuloma of the penis: An uncommon lesion with unusual presentation. *Curr Urol*. 2017;9(4):216-8. <https://doi.org/10.1159/000447144> PMID:28413384 PMCID:PMC5385862
22. Zhao J, Feng Q, Shi S. Pyogenic granuloma of the esophagus. *Clin Gastroenterol Hepatol*. 2017. <https://doi.org/10.1016/j.cgh.2017.03.028>
23. Romero Mascarell C, García Pagán JC, Araujo IK, Llach J, González-Suárez B. Pyogenic granuloma in the jejunum successfully removed by single-balloon enteroscopy. *Rev Esp Enferm Dig*. 2017;109(2):152-4. PMID:28196424
24. Qiu X, Dong Z, Zhang J, Yu J. Lobular capillary hemangioma of the tracheobronchial tree: A case report and literature review. *Medicine (Baltimore)*. 2016;95(48):e5499. <https://doi.org/10.1097/MD.0000000000005499> PMID:27902613 PMCID:PMC5134768
25. Misawa S, Sakamoto H, Kurogochi A, Kirii Y, Nakamura S, Misawa T, Yoneda S, Hirano M, Owa O, Takagi H, Ota H. Rare cause of severe anemia due to pyogenic granuloma in the jejunum. *BMC Gastroenterol*. 2015;15:126. <https://doi.org/10.1186/s12876-015-0355-6> PMID:26444414 PMCID:PMC4596517
26. Matsuzaki K, Imamura Y, Ozawa M, Nakajima T, Ikeda A, Konishi T, Jikuya T. Intravenous lobular capillary hemangioma in the subclavian vein. *Ann Thorac Surg*. 2016;102(5):e427-9. <https://doi.org/10.1016/j.athoracsur.2016.04.013> PMID:27772599
27. Brightman LA, Geronemus RG, Reddy KK. Laser treatment of port-wine stains. *Clin Cosmet Investig Dermatol*. 2015;8:27-33. PMID:25624768 PMCID:PMC4296879
28. Wollina U, Zielinski M, Knopf B, Hipler C. [Eruptive capillary hemangioma following argon laser therapy of naevus flammeus]. *Hautarzt*. 1989;40(4):212-4. PMID:2732049
29. Rana R, Ramachandra SS, Prasad UC, Aggarwal P, Dayakara JK. Recurrent pyogenic granuloma with a satellite lesion. *Cutis*. 2015;96(2):E27-30. PMID:26367761
30. Gupta V, Mridha AR, Sharma VK. Pediatric Dermatology Photoquiz: Multiple erythematous papules on the back. Recurrent pyogenic granulomas with satellitosis. *Pediatr Dermatol*. 2016;33(1):97-8. <https://doi.org/10.1111/pde.12700> PMID:26758098
31. Putra J, Rymeski B, Merrow AC, Dasgupta R, Gupta A. Four cases of pediatric deep-seated/subcutaneous pyogenic granuloma: Review of literature and differential diagnosis. *J Cutan Pathol*. 2017. <https://doi.org/10.1111/cup.12923> PMID:28233342
32. Ryan P, Aarons S, Murray D, Markham T, O'Sullivan S, Lyons F, Lee G, Fitzgibbon J. Human herpesvirus 8 (HHV-8) detected in two patients with Kaposi's sarcoma-like pyogenic granuloma. *J Clin Pathol*. 2002;55(8):619-22. <https://doi.org/10.1136/jcp.55.8.619> PMID:12147659 PMCID:PMC1769721
33. Bains A, Vedant D, Shanker V, Tegta GR. Primary cutaneous anaplastic large cell lymphoma masquerading as large pyogenic granuloma. *Indian Dermatol Online J*. 2016;7(6):526-8. <https://doi.org/10.4103/2229-5178.193896> PMID:27990392 PMCID:PMC5134171
34. Kumar P, Das A, Mondal A, Savant SS. Pyogenic granuloma-like basal cell carcinoma on the abdomen: A deceptive presentation. *Indian Dermatol Online J*. 2016;7(5):446-448. <https://doi.org/10.4103/2229-5178.190502> PMID:27730056 PMCID:PMC5038121
35. Jafarian F, Powell J, Kokta V, Champagne M, Hatami A, McCuaig C, Marcoux D, Savard P. Malignant melanoma in childhood and adolescence: report of 13 cases. *J Am Acad Dermatol*. 2005;53(5):816-22. <https://doi.org/10.1016/j.jaad.2005.07.013> PMID:16243130
36. Khader A, Ambooken B, Binitha MP, Francis S, Kuttiyil AK, Sureshan DN. Disseminated cutaneous due to *Cladophialophora bantiana*. *Indian J Dermatol Venereol Leprol*. 2015;81(5):491-4. <https://doi.org/10.4103/0378-6323.162333> PMID:26261143
37. Bolton JG, Galeckas KJ, Satter EK. Inoculation bartonellosis in an adult: a case report. *Cutis*. 2010;85(1):37-42. PMID:20184210
38. Al-Mohaya MA, Al-Malik AM. Excision of oral pyogenic granuloma in a diabetic patient with 940nm diode laser. *Saudi Med J*. 2016;37(12):1395-1400. <https://doi.org/10.15537/smj.2016.12.15941> PMID:27874157 PMCID:PMC5303780
39. Hasanoglu Erbasar GN, Senguven B, Gultekin SE, Cetiner S. Management of a recurrent pyogenic granuloma of the hard palate with diode laser: A case report. *J Lasers Med Sci*. 2016;7(1):56-61. <https://doi.org/10.15171/jlms.2016.12> PMID:27330700 PMCID:PMC4908978
40. Wollina U. Three hundred patients treated with ultrapulsed 980 nm diode laser for skin disorders. *Indian J Dermatol*. 2016;61(5):540-4. <https://doi.org/10.4103/0019-5154.190111> PMID:27688445 PMCID:PMC5029241
41. Au S, Fancher W, Scribner J. Treatment of pediatric pyogenic granuloma in a functionally and cosmetically sensitive area with the 1064nm Nd:Yag laser. *Dermatol Online J*. 2016;22(4). PMID:27617472
42. Goldman A, Rossata F, Wollina U. Versatility of the Nd-YAG laser in the treatment of facial vascular alterations. *Kosmet Med* 2008;29:134-7.
43. Fekrazad R, Nokhbatolfoghahaei H, Khoei F, Kalhori KA. Pyogenic granuloma: surgical treatment with Er:YAG laser. *J Lasers Med Sci*. 2014;5(4):199-205. PMID:25653822 PMCID:PMC4281984
44. Truschneegg A, Acham S, Kqiku L, Beham A, Jakse N. CO2 laser excision of a pyogenic granuloma associated with dental implants: A case report and review of the literature. *Photomed Laser Surg*. 2016;34(9):425-31. PMID:27420917
45. Liu J, Zhou BR, Yi F, Wu HJ, Zhang JA, Luo D. Pyogenic granuloma in a patient with psoriasis successfully treated by 5-aminolevulinic acid photodynamic therapy: A case report. *Exp Ther Med*. 2016;11(11):345-347. PMID:26889266
46. Wine Lee L, Goff KL, Lam JM, Low DW, Yan AC, Castelo-Soccio L. Treatment of pediatric pyogenic granulomas using  $\beta$ -adrenergic receptor antagonists. *Pediatr Dermatol*. 2014;31(2):203-7. <https://doi.org/10.1111/pde.12217> PMID:24138457
47. Piraccini BM, Alessandrini A, Dika E, Starace M, Patrizi A, Neri I. Topical propranolol 1% cream for pyogenic granulomas of the nail: open-label study in 10 patients. *J Eur Acad Dermatol Venereol*. 2016;30(5):901-2. <https://doi.org/10.1111/jdv.13071> PMID:25708373
48. Oke I, Alkharashi M, Petersen RA, Ashenberg A, Shah AS. Treatment of ocular pyogenic granuloma with topical timolol. *JAMA Ophthalmol*. 2017;135(4):383-5. <https://doi.org/10.1001/jamaophthalmol.2017.0110> PMID:28301661
49. de Graaf M, Breur JM, Raphaël MF, Vos M, Breugem CC, Pasmans SG. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. *J Am Acad Dermatol*. 2011;65(2):320-7. <https://doi.org/10.1016/j.jaad.2010.06.048> PMID:21601311
50. Müller ME, van der Velde N, Krulder JW, van der Cammen TJ. Syncope and falls due to timolol eye drops. *BMJ*. 2006;332(7547):960-1. <https://doi.org/10.1136/bmj.332.7547.960> PMID:16627515 PMCID:PMC1444852